May A, Schulte LH (2016) Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 12(8):455–464
Article CAS PubMed Google Scholar
Burch RC, Buse DC, Lipton RB, Migraine (2019) Epidemiology, Burden, and Comorbidity. Neurol Clin 37(4):631–649
Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H et al (2018) Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain 19(1):50
Article PubMed PubMed Central Google Scholar
Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ et al (2020) Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain 21(1):23
Article CAS PubMed PubMed Central Google Scholar
Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12(10):575–583
Al Ghadeer HA, AlSalman SA, Albaqshi FM, Alsuliman SR, Alsowailem FA, Albusror HA et al (2021) Quality of life and disability among Migraine patients: a single-center study in AlAhsa, Saudi Arabia. Cureus 13(11):e19210
PubMed PubMed Central Google Scholar
Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A et al (2016) Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc. ;S0025-6196(16)00126-9
Schytz HW, Amin FM, Jensen RH, Carlsen L, Maarbjerg S, Lund N et al (2020) Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, J Headache Pain. 2021;22(1):22
Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F et al (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20(1):92
Article PubMed PubMed Central Google Scholar
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia Int J Headache 35(6):478–488
Berger A, Bloudek LM, Varon SF, Oster G (2012) Adherence with migraine prophylaxis in clinical practice. Pain Pract off J World Inst Pain 12(7):541–549
Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB et al (2015) Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 86(9):996–1001
Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody Therapy added to OnabotulinumtoxinA: a Retrospective Chart Review. Pain Ther 10(2):809–826
Article PubMed PubMed Central Google Scholar
T S, K B, A T. Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review. Front Pain Res Lausanne Switz [Internet]. (2023) Mar 17 [cited 2024 Jan 7];4. Available from: https://pubmed.ncbi.nlm.nih.gov/37006413/
Alpuente A, Torres-Ferrus M, Terwindt GM (2023) Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache. Cephalalgia 43(3):033310242211502
Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain 23(1):67
Article PubMed PubMed Central Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg Lond Engl 8(5):336–341
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology [Internet]. 2020 Mar 31 [cited 2024 Jan 7];94(13). Available from: https://www.neurology.org/doi/https://doi.org/10.1212/WNL.0000000000009169
Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092–1101
Article PubMed PubMed Central Google Scholar
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221
Article CAS PubMed PubMed Central Google Scholar
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434
Article CAS PubMed Google Scholar
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the Preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122
Article CAS PubMed Google Scholar
Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 43(2):1273–1280
Curone M, Tullo V, Didier HA, Bussone G (2022) Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 43(9):5759–5761
Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21(1):69
Article CAS PubMed PubMed Central Google Scholar
Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61
Article CAS PubMed PubMed Central Google Scholar
Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-term effectiveness of three Anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36(2):191–202
Article CAS PubMed PubMed Central Google Scholar
Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U et al (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92(20):e2309–e2320
Article CAS PubMed PubMed Central Google Scholar
Krymchantowski AV, Jevoux C, Krymchantowski AG, Silva-Néto RP (2023) Monoclonal antibodies for chronic migraine and medication overuse headache: a real-world study. Front Neurol 14:1129439
Article PubMed PubMed Central Google Scholar
Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G et al (2022) Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia Int J Headache 42(7):645–653
Barbanti P, Egeo G, Aurilia C, Altamura C, d’Onofrio F, Finocchi C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138
Article CAS PubMed PubMed Central Google Scholar
Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol 29(5):1505–1513
Ailani J, Pearlman E, Zhang Q, Nagy AJ, Schuh K, Aurora SK (2020) Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. Eur J Neurol 27(3):542–549
Article CAS PubMed Google Scholar
Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrús M, Pozo-Rosich P (2021) Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study. Eur J Neurol 28(7):2378–2382
Iannone LF, Fattori D, Marangoni M, Benemei S, Chiarugi A, Geppetti P et al (2023) Switching OnabotulinumtoxinA to monoclonal Anti-CGRP antibodies in drug-resistant chronic migraine. CNS Drugs 37(2):189–202
Article CAS PubMed Google Scholar
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U et al (2023) Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl 402(10404):775–785
Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32
Article CAS PubMed PubMed Central Google Scholar
Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia Int J Headache 43(3):3331024231152169
Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia Int J Headache 43(4):3331024231159366
Kopruszinski CM, Xie JY, Eyde NM, Remeniuk B, Walter S, Stratton J et al (2017) Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-r
留言 (0)